Anika Therapeutics (ANIK) Proxy filing summary

Voting matters and shareholder proposals

• Proposal 4 seeks approval of the seventh amendment and restatement of the 2017 Omnibus Incentive Plan, following an unfavorable ISS recommendation due to dilution concerns.

• The board unanimously recommends a vote in favor of the Seventh Amended Plan, which maintains a fungible rate of 2.0 common shares per full-value award.

• Stockholders can change or revoke their proxy votes before the meeting through various methods, including written notification, internet, or submitting a new proxy card.

• All solicitation costs are borne by the company, with reimbursement for reasonable expenses to intermediaries.

Executive compensation and say-on-pay

• The Seventh Amended Plan continues to use a fungible plan design, assigning a higher cost to full-value awards and reducing the share pool accordingly.

• Phantom RSUs and PRSUs granted in recent years are recorded as liabilities due to expected cash settlement from potential share shortages.

Board of directors and corporate governance

• The board approved the Seventh Amended Plan on April 26, 2026, and recommends its adoption by shareholders.